Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study | Zendy

Mark Underwood | Zendy; Joe Horton | Zendy; Keith Nangle | Zendy; Judy Hopking | Zendy; Kimberly Y. Smith | Zendy; Michael Aboud | Zendy; Brian Wynne | Zendy; Jörg Sievers | Zendy; Eugene L. Stewart | Zendy; Ruolan Wang | Zendy

Open Access

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Author(s) -

Mark Underwood,

Joe Horton,

Keith Nangle,

Judy Hopking,

Kimberly Y. Smith,

Michael Aboud,

Brian Wynne,

Jörg Sievers,

Eugene L. Stewart,

Ruolan Wang

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01643-21

Subject(s) - dolutegravir , integrase , integrase inhibitor , virology , raltegravir , elvitegravir , nucleoside reverse transcriptase inhibitor , drug resistance , medicine , biology , pharmacology , viral load , human immunodeficiency virus (hiv) , genetics , antiretroviral therapy

At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. Here, we report emergent HIV-1 drug resistance and mechanistic underpinnings among dolutegravir-treated adults in DAWNING.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research